ON MY MIND

Return to Play With Genetic Heart Disease: The Importance of Developing a Personalized Emergency Action Plan

Belinda Gray^(D), MBBS, PhD; Rachel Lampert^(D), MD; Michael Papadakis^(D), MD

🗪 udden cardiac death (SCD), while rare, is the most common cause of death for athletes during sports. Historically, athletes diagnosed with genetic heart diseases were subjected to blanket restrictions on sport participation because of theorized risks of exercise. More recently, observational evidence is emerging showing that when managed in expert settings with guideline based risk-stratification and management, athletes with many inherited cardiac conditions have low rates of breakthrough cardiac events.¹⁻³ The prospective multicenter observational study, LIVE-HCM (Lifestyle and Exercise in Hypertrophic Cardiomyopathy), demonstrated no increased risk of events in individuals with HCM who exercised at a vigorous intensity compared with nonvigorous exercisers, with event-rates of 15.9 and 15.3 per 1000 person-years, respectively.⁴ Similar results were also seen in several smaller studies of athletes with HCM, where continued participation in competitive sports was not associated with excess of serious events. Long QT syndrome (LQTS) is another condition with data demonstrating low risk of exerciseinduced arrhythmias in optimally treated patients. The prospective multicenter LIVE-LQT demonstrated low overall event rates in LQTS patients with contemporary management, and no difference in event-rate between vigorous and nonvigorous exercisers (8.3 vs 8.6 per 1000 person-years). Small studies of LOTS patients continuing to participate in sports show similarly low eventrates. Even individuals with defibrillator implants, who are by definition *high risk*, have not shown serious adverse events in competitive athletes or in those participating in high-risk sports, such as surfing.¹ For other conditions, such as arrhythmogenic cardiomyopathy (particularly *PKP-2*–mediated disease), there is a increased risk of heart failure, ventricular arrhythmias, and sudden death for individuals continuing to exercise, which highlights the importance of expert assessment and personalized risk stratification within a specialized multidisciplinary clinic.^{1,3} Based on these data, recent professional society statements from European Society of Cardiology (2020), American Heart Association/American College of Cardiology (2024), and Heart Rhythm Society (2024) have evolved; now, participation in sports for many athletes with genetic heart disease "*may be considered*" (2b) or "*is reasonable*" (2a).^{1,2}

Shared decision-making forms an increasingly important part of the expert consultation for athletes with genetic heart disease.^{1-3,5} Shared decision-making involves a personalized discussion and evaluation of risk and risk tolerance, reviewing the best evidence available, and limitations of that data, understanding uncertainties and any controversies, and a discussion of values and preferences of the athlete.^{1,5} Shared decision-making models of care empower athletes to make an informed decision about their care as part of a patient-centered care model. Shared decision-making incorporates all stakeholders in the athlete's care including the athlete, their family, their school or club, and often the sport's governing bodies.

As the focus moves away from a binary clearance model and toward facilitating return-to-play for athletes as part of a shared decision-making model, the importance of logistic and practical aspects to mitigate potential risk is emerging. The concept of emergency action planning for the population at large is well described. It is

Key Words: athletes = cardiomyopathies = death, sudden, cardiac = decision making, shared = return to sport

© 2025 American Heart Association, Inc.

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

Correspondence to: Belinda Gray, MBBS, PhD, Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia. Email belinda.gray@sydney.edu.au For Sources of Funding and Disclosures, see page 895.

Circulation is available at www.ahajournals.org/journal/circ

recommended that clubs, schools, and sporting organizations develop emergency action plans (EAP) in the event of sudden cardiac arrest (SCA) for all team-members, to include education on recognition of signs of SCA, CPR training, access to early defibrillation with automated external defibrillators on site, and clear plans for dispatch and transport to medical facilities for further management.

While less well recognized than population-focused EAPs, the concept of a personalized EAP (pEAP) is emerging for athletes who are working toward returning to play and have a known SCA risk—carrying genetic heart disease.¹ While exercise may not increase the risk of SCA for some CV disease, such as HCM or LQTS on optimal therapy, these individuals still carry a risk of SCA, which may occur during exercise.⁴ The pEAP is of particular importance when the athlete may be placed in circumstances, such as collision sports or sports in or on water, where an arrhythmic event may place the athlete at higher risk than an event occurring at other times.

This document should be prepared jointly by the athlete and the cardiologist, with input from school/club where relevant. The pEAP should include both standard EAP practices, with the additional inclusion of personalized plans tailored to the specific sport and clinical situation for that athlete, with the goal of successful management of the worst-case scenario for the athlete. Situations which have not been carefully planned or thought out can lead to critical time delays and may be the difference between a successful or unsuccessful resuscitation. We propose that implementation of a pEAP is a key part of facilitating return to play for athletes with genetic heart disease who have elected to return to sports after a comprehensive shared decision making process. A comprehensive pEAP for an HCM patient planning an open water swim, for example, should outline critical elements that may be encountered by the athlete when returning to play (see Figure). First, precautionary measures should be outlined (eg, monitoring, training of support crew). Next, potential risks and adverse events based on the sport and clinical condition should be identified (eg, loss of consciousness in the water). Finally, response to these including the specific prescribed roles and action for all personnel required to act in case of an emergency should be outlined.

As data emerges showing that athletes can participate without excessive risk, as well as the recent, more supportive return-to-play guidelines for some genetic heart diseases, development of pathways to minimize risk




Figure. Example pEAP for patient with HCM.

XX's replace identifiable information in this example. pEAP for a patient with HCM (age, 47 years) who has elected to participate in a ≈20-km open-water ocean swimming event after comprehensive assessment and discussion in shared decision-making model of care. AED indicates automated external defibrillator; CPR, cardiopulmonary resuscitation; HCM, hypertrophic cardiomyopathy; ICD, implanted cardioverter-defibrillator; pEAP, personalized emergency action plan; and VHF, very high frequency.

FRAME OF REFERENCE

through careful personalized risk assessment and management plans, including the development of pEAPs, are critical.¹ For athletes who elect to continue sports despite risk, the process of developing a pEAP is a critical part of the shared-decision making model of care, and may take some time. Genetic heart diseases do carry a risk of SCA/SCD, but with appropriate risk-assessment, treatment, and pEAP, exercise may not increase the risk of SCA for some, beyond the risk of event during activities of daily living. By developing a pEAP together and ensuring all stakeholders, including athlete, family, and club/ association, are well informed of potential risks and outcomes, the worst-case scenario is clearly highlighted. Relatedly, the pEAP also helps to emphasize the seriousness of the risks; indeed, some athletes may modify their decision to return to certain sports on development. The development of a pEAP is a critical part of the shared decision-making model of care, and takes time, with "worst-case scenario" situations clearly described and the patient and stakeholders, well-informed of all potential risks and outcomes.

ARTICLE INFORMATION

Affiliations

Faculty of Medicine and Health, University of Sydney; and Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia (B.G.). Yale School of Medi-

cine, New Haven, CT (R.L.). Cardiovascular Clinical Academic Group, St George's University of London, United Kingdom (M.P.).

Sources of Funding

Dr Gray is the recipient of a Heart Foundation Future Leader Fellowship (No. 107244).

Disclosures

Dr Papadakis is a consultant for Cardiac Risk in the Young (CRY).

REFERENCES

- Lampert R, Chung EH, Ackerman MJ, Arroyo AR, Darden D, Deo R, Dolan J, Etheridge SP, Gray BR, Harmon KG, et al. 2024 HRS expert consensus statement on arrhythmias in the athlete: evaluation, treatment, and return to play. *Heart Rhythm.* 2024;21:e151–e252. doi: 10.1016/j.hrthm.2024.05.018
- Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, et al; Peer Review Committee Members. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*. 2024;149:e1239–e1311. doi: 10.1161/CIR.000000000001250
- Pelliccia A, Sharma S, Gati S, Back M, Borjesson M, Caselli S, Collet JP, Corrado D, Drezner JA, Halle M, et al; ESC Scientific Document Group. 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease. *Eur Heart J.* 2021;42:17–96. doi: 10.1093/eurheartj/ehaa605
- Lampert R, Ackerman MJ, Marino BS, Burg M, Ainsworth B, Salberg L, Esteban MTT, Ho CY, Abraham R, Balaji S, et al. Vigorous exercise in patients with hypertrophic cardiomyopathy. *JAMA Cardiol*. 2023;8:595–605.
- Martinez MW, Ackerman MJ, Annas GJ, Baggish AL, Day SM, Harmon KG, Kim JH, Levine BD, Putukian M, Lampert R. Sports participation by athletes with cardiovascular disease. *J Am Coll Cardiol.* 2024;83:865–868. doi: 10.1016/j.jacc.2023.12.021